Cost-effectiveness analysis of low-dose direct oral anticoagulant (DOAC) for the prevention of cancer-associated thrombosis in the United States.

Ang Li Josh J CarlsonNicole M KudererJordan K SchaeferShan LiDavid A GarciaAlok A KhoranaMarc CarrierGary H Lyman

Published in: Cancer (2020)

Low-dose DOAC thromboprophylaxis for 6 months appears to be cost-effective in patients with cancer who are at intermediate-to-high risk for VTE. The implementation of this strategy in patients with Khorana scores ≥3 may lead to the highest cost-benefit ratio.

Keyphrases

venous thromboembolism
direct oral anticoagulants
low dose
high dose
atrial fibrillation
primary care
pulmonary embolism
healthcare
quality improvement